<p>miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway</p>-Reference-Cited by-同舟云学术

miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway

Published:2020-07 Issue: Volume:Volume 13 Page:7213-7227
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Shao Qing-Ping,Wei Chen,Yang Jie,Zhang Wen-Zhou

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference80 articles.

1. Targeting renal cell carcinoma with a HIF-2 antagonist

2. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

3. miRNA networks modulate human endothelial cell adaptation to cyclic hypoxia

4. HIF-2α and Oct4 have synergistic effects on survival and myocardial repair of very small embryonic-like mesenchymal stem cells in infarcted hearts

5. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EPAS1/HIF-2α Acts as an Unanticipated Tumor-Suppressive Role in Papillary Thyroid Carcinoma;International Journal of General Medicine;2023-05

2. TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs;Cell Death & Disease;2023-01-27

3. A cohesin‐associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma;FEBS Open Bio;2022-09-02

4. EPAS1 Promoter Hypermethylation is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer;Genetic Testing and Molecular Biomarkers;2022-08-01

5. Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA;Frontiers in Oncology;2022-05-30